Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab for Post-Cardiac Arrest Inflammation
NCT03863015Phase 2Completed
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of tocilizumab in Systemic Inflammatory Response Syndrome (SIRS), cardiac arrest (SCA). Started Mar 2019; status: completed.
02
Drugs
tocilizumab
03
Conditions
Systemic Inflammatory Response Syndrome (SIRS)cardiac arrest (SCA)
Beyond the preview
Go deeper on NCT03863015.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03863015.